Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Lineage Cell Therapeutics Zoomed Higher Today


Clinical-stage biotech Lineage Cell Therapeutics (NYSEMKT: LCTX) was a bright spot during a dark session for the overall stock market. The company's shares rocketed upward by more than 21% on Monday on news of a collaboration agreement with a large and deep-pocketed partner.

On Monday morning, Lineage disclosed that it and its Cell Cure Neurosciences subsidiary had signed a global collaboration and licensing deal with two units of Swiss healthcare powerhouse Roche Holding (OTC: RHHBY).

Image source: Getty Images.

Continue reading


Source Fool.com

Like: 0
Share

Comments